Related Experiment Video
Updated: Dec 25, 2025
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?
Giovanni Monteleone1, Sandro Ardizzone2
1Department of Systems Medicine, University of Rome 'TOR VERGATA', Rome, Italy.
Insights
Inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis may not increase SARS-CoV-2 infection risk. Cytokine blockers used for IBD might protect against severe COVID-19 pneumonia.
Area of Science:
- Gastroenterology
- Immunology
- Virology
Background:
- Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic immune-inflammatory conditions influenced by genetics and environment.
- IBD and its treatments can increase patient susceptibility to complications and comorbidities.
- The COVID-19 pandemic raises concerns for IBD patients due to potential increased morbidity and mortality in those with comorbidities.
Purpose of the Study:
- To review the mechanisms of SARS-CoV-2 infection and its relationship with intestinal inflammation.
- To explore reasons why the IBD population may not face an elevated risk of SARS-CoV-2 infection.
- To highlight the potential protective role of cytokine blockers against COVID-19 pneumonia in IBD patients.
Main Methods:
- Literature review and synthesis of current research on SARS-CoV-2 infection pathways.
- Analysis of the interplay between viral mechanisms and intestinal inflammation in IBD.
- Evaluation of existing therapeutic strategies for IBD in the context of COVID-19.
Main Results:
- SARS-CoV-2 infects cells through specific factors and mechanisms that can potentially link to intestinal inflammation.
- Evidence suggests the general IBD population might not have a higher risk of contracting SARS-CoV-2.
- Cytokine blockers, a treatment for IBD, show potential in preventing severe COVID-19 pneumonia.
Conclusions:
- Understanding SARS-CoV-2 infection mechanisms is crucial for managing IBD patients during the pandemic.
- The IBD population may not be at increased risk for SARS-CoV-2 infection, contrary to initial concerns.
- Targeted therapies like cytokine blockers could offer a protective strategy against COVID-19 complications in IBD patients.
Abstract:
Crohn's disease [CD] and ulcerative colitis [UC], the main inflammatory bowel diseases [IBD] in humans, are chronic, immune-inflammatory diseases, the pathogenesis of which suggests a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant today, as coronavirus disease [Covid-19] has rapidly spread from China to countries where IBD are more prevalent, and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infects cells and to illustrate the link between such determinants and intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk of developing SARS-CoV-2 infection and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia.
More Related Videos
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD: